Skip to the care guide
Tesamorelin The care checkbook Chapter index
Open the guide
Start with the reason
Check the person
Check the medicine
Check the visit
Take your questions
Check the full bill
Check risks and follow-up
Check the evidence
Care guide / Check the evidence
Check what the studies actually found.
“Works” is a loose word. A useful claim names the people studied, what changed and how the result was measured.
Read this chapter ↓
Keep this question
Who was studied?
Belly-fat results are not weight-loss results
The September 2026 US label approves tesamorelin (Egrifta SV, Egrifta WR) for reducing excess abdominal fat in adults with HIV and lipodystrophy.
HIV is a virus; lipodystrophy means fat has shifted in the body.
Deep abdominal fat means fat around the internal organs, not just a change on the scales.
The main studies saw little change in body weight; weight-loss care is excluded by the label.
What the first large paper found
Falutz’s 2007 trial included 412 people: adults living with HIV who had excess belly fat.
After 26 weeks, deep belly fat fell 15.2% with tesamorelin and rose 5.0% with a dummy injection.
The dummy injection is called a placebo; it does not contain the study medicine.
The result describes a group in a study. Ask how the people in that group compare with you before treating the result as an expectation.
The follow-up changes the question
In the main trials, people switched to a dummy injection after 26 weeks regained deep belly fat over the next 26 weeks.
Ask how long the proposed plan might last and when its value would be reviewed.
Do not stretch a study into a new use
As of September 2026, research on thinking tests did not make tesamorelin an approved treatment for memory loss or ageing.
In an earlier study, older adults taking tesamorelin had slightly better thinking-test scores, including on skills used to plan and organise.
In a later study of people with HIV, thinking-test results did not clearly differ between those taking tesamorelin and those getting usual care.
Ask whether a higher test score would mean a useful change in daily life for you.
A claim about another goal needs evidence for that goal. Ask for the actual paper, not just a summary on the service’s page.
Who took part, and did they have the same health problem?
What did the study compare the medicine with?
What changed, and was that the change I want?
What happened during follow-up?
If the paper cannot answer those questions, keep the claim open rather than filling in the blanks.
Source notes for this chapter
PubMed: the first large tesamorelin trial
For the paper’s results in deep belly fat.
PubMed: a further trial and treatment follow-up
For the loss of the initial improvement after switching to a dummy injection.
DailyMed: tesamorelin (Egrifta WR) label
For the approved use and weight and heart limits.
PubMed: research on thinking tests
For research outside the approved use.
PubMed: research on thinking in people with HIV
For the comparison with usual care in the HIV study.
← Check risks and follow-up Return to the guide →
This checkbook helps you question tesamorelin care; it is a guide, never a clinic or a place that sells treatment.
Guide opening Back to the chapter top ↑ Read the text copy